JenaValve Technology, Inc., a Wilmington, DE- and Munich, Germany-based developer of transcatheter aortic valve implantation systems for aortic valve disease, raised an additional $10m in Series C venture funding.
Backers included new investors Valiance Asset Management and RMM and current investors Edmond de Rothschild Investment Partners, Atlas Venture Fund, NeoMed Management, VI Partners AG, Sunstone Capital, Gimv (GIMB.EN), Legend Capital and Omega Funds. In conjunction with the funding, industry veteran Jan Keltjen joined JenaValve’s board of directors, while life sciences entrepreneur and financier Rudi Mariën joined as an observer.
The Series C round now totals $72.5m, having the company raised $62.5m in 2013 (read here)
Founded in 2006 by cardiologists and inventors Prof. Hans R. Figulla, M.D. and Prof. Markus Ferrari, M.D. and led by Helmut J. Straubiger, CEO, JenaValve Technology develops, manufactures and markets transcatheter aortic valve implantation systems (TAVI) to treat patients suffering from aortic valve disease.
The company’s transapical TAVI system is currently being sold in Europe and other markets worldwide. The transfemoral TAVI system entered into a first-in-man clinical study at the end of 2013 and is anticipated to be commercially available for sale in 2015.